In this issue:
First-line nivolumab vs chemotherapy in NSCLC
Tracking the evolution of NSCLC
Oncogenic genetic alterations in adenocarcinoma in the young
Promising long-term alectinib data in ALK+ NSCLC
Multikinase inhibitors in RET-rearranged NSCLC
CRP levels predict mortality in operable lung cancer
Pembrolizumab active in PD-L1+ MPM?
Prophylactic cranial irradiation: no benefit in ES SCLC
Comparing chemoradiation regimens in stage 3 NSCLC
Which chemotherapy regimen for LNEC?
Please login below to download this issue (PDF)